HALUK ONAT, EMİN DARENDELİLER, NURCAN ERTÜRK, MÜNİR KIRAY, NAKİYE ÖZTÜRK, NİJAD BİLGE, HALUK ANDER, FAUK AYKAN
İ.Ü. Onkoloji Enstitüsü Tıbbi Onkoloji BD
Twenty three consecutive early stage nonseminornatosis testicular carcinoma patients who are accepted as high risk after unilateral inguinal orchiectorny are treated with chemotherapy. There were 10 stage I patients with 6 of them having high serum tumour marker (HCG and/or AFP), 1 of them having high serum markers and spermatic cord invasion and 3 of them having vascular invasion. There were 13 stage II patients. Chemotherapy regimens PEB or POMB/ ACE were given according to the extent of disease for 4 courses. The mean age of the whole patients was 25.7 years and they are still on close follow up for median 20 months. There is no relapse yet in any of the stage I patients and the 2 year disease free survival is % 100. There were 9 complete and 2 partial responses in stage II patients and the residual masses were removed surgically in these 2 patients who are followed with no evidence of disease. The disease free survival in stage II was % 87.5. High risk stage I patients with nonseminornatosis testicular carcinoma should be treated with chemotherapy for a short time to achieve cure. The standard treatment model for stage II patients should be chemotherapy followed by surgical remove for residual masses after chemotherapy.
Keywords :
